Finding the seed of recurrence: Hepatocellular carcinoma circulating tumor cells and their potential to drive the surgical treatment
Open Access
- 27 September 2021
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Surgery
- Vol. 13 (9), 967-978
- https://doi.org/10.4240/wjgs.v13.i9.967
Abstract
The treatment for hepatocellular carcinoma (HCC) relies on liver resection, which is, however, burdened by a high rate of recurrence after surgery, up to 60% at 5 years. No pre-operative tools are currently available to assess the recurrence risk tailored to every single patient. Recently liquid biopsy has shown interesting results in diagnosis, prognosis and treatment allocation strategies in other types of cancers, since its ability to identify circulating tumor cells (CTCs) derived from the primary tumor. Those cells were advocated to be responsible for the majority of cases of recurrence and cancer-related deaths for HCC. In fact, after being modified by the epithelial-mesenchymal transition, CTCs circulate as “seeds” in peripheral blood, then reach the target organ as dormant cells which could be subsequently “awakened” and activated, and then initiate metastasis. Their presence may justify the disagreement registered in terms of efficacy of anatomic vs non-anatomic resections, particularly in the case of microvascular invasion, which has been recently pointed as a histological sign of the spread of those cells. Thus, their presence, also in the early stages, may justify the recurrence event also in the contest of liver transplant. Understanding the mechanism behind the tumor progression may allow improving the treatment selection according to the biological patient-based characteristics. Moreover, it may drive the development of novel biological tailored tests which could address a specific patient to neoadjuvant or adjuvant strategies, and in perspective, it could also become a new method to allocate organs for transplantation, according to the risk of relapse after liver transplant. The present paper will describe the most recent evidence on the role of CTCs in determining the relapse of HCC, highlighting their potential clinical implication as novel tumor behavior biomarkers able to influence the surgical choice.Keywords
This publication has 63 references indexed in Scilit:
- Presence of EpCAM‐positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinomaInternational Journal of Cancer, 2013
- A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic VariabilityAnnals of Surgical Oncology, 2012
- Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancerCancer and Metastasis Reviews, 2012
- Analysis of Factors Affecting Recurrence of Hepatocellular Carcinoma After Liver Transplantation With a Special Focus on Inflammation MarkersTransplantation, 2011
- Vimentin in cancer and its potential as a molecular target for cancer therapyCellular and Molecular Life Sciences, 2011
- Isolation of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Using a Novel Cell Separation StrategyClinical Cancer Research, 2011
- Epithelial–mesenchymal transition in hepatocellular carcinomaFuture Oncology, 2009
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerThe New England Journal of Medicine, 2004
- Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with CirrhosisThe New England Journal of Medicine, 1996
- Endometriosis and In Vitro FertilizationSeminars in Reproductive Medicine, 1985